Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
IMDX
Insight Molecular Diagnostics Inc.
IMDX directly provides Laboratory Testing & Advisory Services via its GraftAssure family (LDTs/kits) for transplant rejection monitoring.
|
$212.93M |
$7.42
-1.07%
|
|
PEPG
PepGen Inc.
PepGen's PGN-EDODM1 is an oligonucleotide therapeutic targeting DM1, aligning directly with Oligonucleotide Therapeutics.
|
$212.21M |
$6.47
-4.01%
|
|
CVRX
CVRx, Inc.
CVRx's Barostim is a neuromodulation device (implantable) that modulates the autonomic nervous system via baroreflex activation for heart failure.
|
$212.09M |
$8.09
-4.26%
|
|
CATX
Perspective Therapeutics, Inc.
Company directly develops and provides radiopharmaceuticals using alpha-emitting Lead-212 for targeted cancer therapy and diagnostic imaging via 203Pb in a theranostic approach.
|
$210.91M |
$2.94
+4.45%
|
|
FENC
Fennec Pharmaceuticals Inc.
Direct product in oncology/supportive care with FDA-approved PEDMARK therapy for cisplatin-induced ototoxicity.
|
$210.13M |
$7.74
+2.45%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
|
PRE
Prenetics Global Limited
Insighta's FRAGMA liquid biopsy enables multi-cancer early detection.
|
$205.73M |
$15.95
-4.81%
|
|
CRDF
Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company focused on oncology therapeutics, with its lead asset targeting cancer (onvansertib).
|
$204.90M |
$3.12
-1.58%
|
|
MDWD
MediWound Ltd.
MediWound's core products are enzymatic proteins/enzymes (NexoBrid, EscharEx) used for wound debridement, aligning with Recombinant Proteins & Enzymes.
|
$203.37M |
$18.68
-3.21%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$201.96M |
$6.24
+12.03%
|
|
GALT
Galectin Therapeutics Inc.
Lead cancer therapy program belapectin demonstrates oncology-focused Biotech activity and immuno-oncology potential.
|
$201.79M |
$3.14
-1.88%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Lead oncology candidate MIE-101 defines CPMV's core product focus in cancer therapy.
|
$199.89M |
$0.50
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$196.42M |
$1.71
+11.44%
|
|
OSUR
OraSure Technologies, Inc.
OraSure's core offerings include diagnostic equipment such as OraQuick rapid tests and molecular diagnostics platforms.
|
$192.35M |
$2.63
-1.13%
|
|
CABA
Cabaletta Bio, Inc.
Core product category: CAR-T cell therapy platform (CARTA) and rese-cel directly produced by Cabaletta.
|
$192.08M |
$2.12
-2.53%
|
|
UTMD
Utah Medical Products, Inc.
Filshie Clip System is a surgical device used in gynecologic procedures, directly aligning with UTMD's Filshie Clip product line.
|
$192.02M |
$59.70
+1.66%
|
|
NTHI
Neonc Technologies Holdings, Inc.
Directly produces oncology-focused biotech therapies; lead programs NEO100/NEO212 targeting brain cancers.
|
$191.59M |
$9.88
+0.56%
|
|
NYXH
Nyxoah S.A.
Genio is a neuromodulation implant system (implantable medical device) for obstructive sleep apnea.
|
$190.92M |
$5.02
+0.20%
|
|
PRQR
ProQR Therapeutics N.V.
ProQR's Axiomer platform uses oligonucleotide-based RNA editing (EONs) to direct ADAR-mediated editing.
|
$190.65M |
$1.76
-16.19%
|
|
INGN
Inogen, Inc.
Company manufactures medical devices and respiratory care equipment (POCs, SOCs, Simeox), a core medical devices business.
|
$190.09M |
$7.04
-2.49%
|
|
NNOX
Nano-X Imaging Ltd.
Directly manufactures diagnostic imaging equipment used for disease detection and monitoring.
|
$189.78M |
$2.96
-1.50%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$188.25M |
$1.87
+5.65%
|
|
CNFN
CFN Enterprises Inc.
CNFN's Ranco segment operates as a contract manufacturer/co-packer and white-label producer for clients.
|
$186.35M |
$1.57
|
|
HUMA
Humacyte, Inc.
Humacyte's Symvess is a vascular conduit/endovascular device used for extremity vascular trauma—fits Vascular Intervention Devices.
|
$185.30M |
$1.18
+0.43%
|
|
SKIN
The Beauty Health Company
High-margin disposable consumables (tips, solutions, serums) sold for Hydrafacial devices create a recurring revenue stream, matching Medical Device Consumables.
|
$185.17M |
$1.46
-6.41%
|
|
TMCI
Treace Medical Concepts, Inc.
Treace's core bunion correction systems are surgical instruments/devices used in operative procedures.
|
$183.20M |
$2.94
-0.84%
|
|
LFMD
LifeMD, Inc.
LifeMD operates as a healthcare services provider with a multi-state medical group and in-house pharmacy; core service delivery.
|
$183.03M |
$3.88
-3.00%
|
|
WALD
Waldencast plc
FDA-approved Obagi saypha MagIQ injectable gel indicates a dermal filler/medical device product line.
|
$181.59M |
$1.50
+2.04%
|
|
EDIT
Editas Medicine, Inc.
Core product category: in vivo gene therapy using Editas's gene-editing platform (AsCas12a) delivered via targeted lipid nanoparticles (tLNP).
|
$178.94M |
$2.04
+2.76%
|
|
AVR
Anteris Technologies Global Corp.
Company directly develops and sells medical devices for the cardiovascular field, specifically the DurAVR transcatheter heart valve and related biomaterial technologies.
|
$178.87M |
$4.91
-1.01%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$177.91M |
$1.45
-2.36%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$177.23M |
$7.24
-1.03%
|
|
INFU
InfuSystem Holdings, Inc.
Advanced wound care devices are a key growth area via its wound care partnerships.
|
$177.09M |
$8.63
-3.79%
|
Showing page 22 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
